Approved antibacterial drugs in the last 10 years: from the bench to the clinic
Bacterial infections constitute one of the major cases of primary medical incidences worldwide. Historically, the fight against bacterial infections in humans has been an ongoing battle, due to the ability of bacteria to adapt and to survive. Indeed, bacteria have developed various mechanisms of res...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2023-06-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100813/100813.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823865712955883520 |
|---|---|
| author | Miguel García-Castro Francisco Sarabia Amelia Díaz-Morilla Juan Manuel López-Romero |
| author_facet | Miguel García-Castro Francisco Sarabia Amelia Díaz-Morilla Juan Manuel López-Romero |
| author_sort | Miguel García-Castro |
| collection | DOAJ |
| description | Bacterial infections constitute one of the major cases of primary medical incidences worldwide. Historically, the fight against bacterial infections in humans has been an ongoing battle, due to the ability of bacteria to adapt and to survive. Indeed, bacteria have developed various mechanisms of resistance against several therapeutic agents. Consequently, the scientific community is always interested in search of new therapeutic agents, which are able to efficiently kill resistant-bacterial strains. This article covers the most recent antibacterial molecules approved by the Food and Drugs Administration (FDA) and European Medicines Agency (EMA) from 2012 to 2022 and intends to focus on synthetic derivatives to give a pedagogical view, with the goal of highlighting the importance of organic synthesis to obtain greater efficacy. A focus will be made on studies describing the structure and activity of the organic molecules and their interactions with their respective biological targets. |
| format | Article |
| id | doaj-art-0d234e3b672d424f80d5032a54f5258b |
| institution | Kabale University |
| issn | 2836-7677 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Open Exploration |
| record_format | Article |
| series | Exploration of Drug Science |
| spelling | doaj-art-0d234e3b672d424f80d5032a54f5258b2025-02-08T06:28:42ZengOpen ExplorationExploration of Drug Science2836-76772023-06-011318020910.37349/eds.2023.00013Approved antibacterial drugs in the last 10 years: from the bench to the clinicMiguel García-Castro0https://orcid.org/0000-0001-6141-2648Francisco Sarabia1Amelia Díaz-Morilla2Juan Manuel López-Romero3Department of Organic Chemistry, Faculty of Sciences, University of Malaga, 29071 Malaga, SpainDepartment of Organic Chemistry, Faculty of Sciences, University of Malaga, 29071 Malaga, SpainDepartment of Organic Chemistry, Faculty of Sciences, University of Malaga, 29071 Malaga, SpainDepartment of Organic Chemistry, Faculty of Sciences, University of Malaga, 29071 Malaga, SpainBacterial infections constitute one of the major cases of primary medical incidences worldwide. Historically, the fight against bacterial infections in humans has been an ongoing battle, due to the ability of bacteria to adapt and to survive. Indeed, bacteria have developed various mechanisms of resistance against several therapeutic agents. Consequently, the scientific community is always interested in search of new therapeutic agents, which are able to efficiently kill resistant-bacterial strains. This article covers the most recent antibacterial molecules approved by the Food and Drugs Administration (FDA) and European Medicines Agency (EMA) from 2012 to 2022 and intends to focus on synthetic derivatives to give a pedagogical view, with the goal of highlighting the importance of organic synthesis to obtain greater efficacy. A focus will be made on studies describing the structure and activity of the organic molecules and their interactions with their respective biological targets.https://www.explorationpub.com/uploads/Article/A100813/100813.pdfantibioticsapproved drugsantibacterial agentsmulti-drug resistanceorganic synthesis |
| spellingShingle | Miguel García-Castro Francisco Sarabia Amelia Díaz-Morilla Juan Manuel López-Romero Approved antibacterial drugs in the last 10 years: from the bench to the clinic Exploration of Drug Science antibiotics approved drugs antibacterial agents multi-drug resistance organic synthesis |
| title | Approved antibacterial drugs in the last 10 years: from the bench to the clinic |
| title_full | Approved antibacterial drugs in the last 10 years: from the bench to the clinic |
| title_fullStr | Approved antibacterial drugs in the last 10 years: from the bench to the clinic |
| title_full_unstemmed | Approved antibacterial drugs in the last 10 years: from the bench to the clinic |
| title_short | Approved antibacterial drugs in the last 10 years: from the bench to the clinic |
| title_sort | approved antibacterial drugs in the last 10 years from the bench to the clinic |
| topic | antibiotics approved drugs antibacterial agents multi-drug resistance organic synthesis |
| url | https://www.explorationpub.com/uploads/Article/A100813/100813.pdf |
| work_keys_str_mv | AT miguelgarciacastro approvedantibacterialdrugsinthelast10yearsfromthebenchtotheclinic AT franciscosarabia approvedantibacterialdrugsinthelast10yearsfromthebenchtotheclinic AT ameliadiazmorilla approvedantibacterialdrugsinthelast10yearsfromthebenchtotheclinic AT juanmanuellopezromero approvedantibacterialdrugsinthelast10yearsfromthebenchtotheclinic |